Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout

Abstract
Cardiovascular risk is increased in patients with gout. We compared cardiovascular outcomes associated with febuxostat, a nonpurine xanthine oxidase inhibitor, with those associated with allopurinol, a purine base analogue xanthine oxidase inhibitor, in patients with gout and cardiovascular disease.
Funding Information
  • Takeda Pharmaceuticals U.S.A.

This publication has 21 references indexed in Scilit: